REFERENCES
- Wingard JR, Merz WG, Rinaldi MG, Johnson TR, Karp JE, Saral R. In-crease in Candida krusei infection among patients with bone marrow trans-plantation and neutropenia treated prophylactically with fluconazol. N Engl J Med. 1991; 325 (18): 1274–7.
- Wingard JR, Merz WG, Rinaldi MG, Miller CB, Karp JE, Saral R. As-sociation of Torulopsis glabrata infections with fluconazol prophylaxis in neutropenic bone marrow transplant patients. Antimicrob Agents Chemother. 1993; 37 (9): 1847–9.
- Krcmery V, Krupova I, Denning DW. Invasive yeast infections other than Candida spp. in acute leukaemia. J Hosp Infect. 1999; 41 (3): 181–94.
- Trifilio S, Singhal S, Williams S, Frankfurt 0, Gordon L, Evens A, et al. Breakthrough fungal infections after allogeneic hematopoietic stem cell transplantation in patients on prophylactic voriconazole. Bone Marrow Transplant. 2007 Sep; 40 (5): 451–6.
- Sun HY, Singh N. Characterisation of breakthrough invasive mycoses in echinocandin recipients: an evidence-based review. Int J Antimicrob Agents. 2010; 35 (3): 211–8.
- Pfaller MA, Diekema DJ, Mendez M, Kibbler C, Erzsebet P, Chang SC, et al. Candida guilliermondii, an opportunistic fungal pathogen with de-creased susceptibility to fluconazol: geographic and temporal trends from the ARTEMIS DISK antifungal surveillance program. J Clin Microbiol. 2006; 44 (10): 3551–6.
- Pfaller MA, Diekema DJ, Colombo AL, Kibbler C, Ng KP, Gibbs DL, et al. Candida rugosa, an emerging fungal pathogen with resistance to azoles: geographic and temporal trends from the ARTEMIS DISK antifungal surveillance program. J Clin Microbiol. 2006; 44 (10): 3578–82.
- Hawkins JL, Baddour LM. Candida lusitaniae infections in the era of fluconazole availability. Clin Infect Dis. 2003; 36 (2): e14–8.
- Martinez M, López-Ribot JL, Kirkpatrick WR, Coco BJ, Bachmann SP, Patterson TF. Replacement of Candida albicans with Candida dublinien-sis in human immunodeficiency virus-infected patients with oropharyngeal candidiasis treated with fluconazole. J Clin Microbiol. 2002; 40 (9): 3135–9.
- Miceli MH, Diaz JA, Lee SA. Emerging opportunistic yeast infections. Lancet Infect Dis. 2011 Feb; 11 (2): 142–51.
- Imhof A, Balajee SA, Fredricks DN, Englund JA, Marr KA. Break-through fungal infections in stem cell transplant recipients receiving voricona-zole. Clin Infect Dis. 2004; 39 (5): 743–6.
- Wingard JR, Merz WG, Rinaldi MG, Johnson TR, Karp JE, Saral R. Increase in Candida krusei infection among patients with bone marrow SSN 1120-009X transplantation and neutropenia treated prophylactically with fluconazole. N Engl J Med. 1991; 325 (18): 1274–7
- Kovacicová G, ry V Jr. Nosocomial candidemia in geriatric pa-tients. J Chemother. 2001; 13 (3): 340–3.
- Krcmery V, Barnes AJ. Non-albicans Candida spp. causing fun-gaemia: pathogenicity and antifungal resistance. J Hosp Infect. 2002; 50 (4): 243–60.
- Pfaller MA, Boyken L, Hollis RJ, Messer SA, Tendolkar S, Diekema DJ.: In vitro susceptibilities of Candida spp. to caspofungin: four years of global surveillance. J Clin Microbiol. 2006 Mar; 44 (3): 760–3.
- Garcia-Efron G, Park S, Lee S, Perlin DS: Echinocandin resistance in clinical Candida spp. isolates. 47th Interscience Conference Antimicrobial Agents and Chemotherapy: Sept 17— 20, 2007: Chicago, IL, USA: 2007: M-2017